Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07564908

Correlation and Heterogeneity of the Immune Microenvironment and Histopathological Growth Patterns in Resectable Colorectal Cancer Liver Metastases

Correlation and Heterogeneity of the Immune Microenvironment and Histopathological Growth Patterns in Resectable Colorectal Cancer Liver Metastases

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

West China Hospital of Sichuan University

Chengdu, Sichuan, 610041, China

About this study

This study aims to retrospectively analyze the status and spatial heterogeneity of the tumor microenvironment (TME) in liver metastases from patients with CRLM, as well as the association between HGPs at the tumor-liver interface and postoperative recurrence following resection of liver metastases. Furthermore, this study seeks to explore the underlying mechanisms through which HGPs influence patient prognosis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with CRLM who underwent R0 resection
  • Histologically or cytologically confirmed CRLM
  • Have sufficient liver metastasis tissue specimens available for analysis
  • Complete treatment and follow-up records

Exclusion criteria

  • Patients did not undergo R0 resection
  • Postoperative specimens were unavailable
  • Clinical data were incomplete.

Treatment and study plan

Formalin-fixed, paraffin-embedded (FFPE) sections of colorectal cancer liver metastases were stained with hematoxylin and eosin (H&E) and Multiplex immunohistochemistry (mIHC) staining.

Other

Formalin-fixed, paraffin-embedded (FFPE) sections of colorectal cancer liver metastases were stained with hematoxylin and eosin (H&E) and Multiplex immunohistochemistry (mIHC) staining.

Primary outcomes

  1. OS(Overall survival)

    Time frame: OS is defined as the time from the date of the first liver metastasis resection to death due to any cause or loss to follow-up, assessed up to 100 months.

    OS was defined as the time from the date of the first liver metastasis resection to death due to any cause or loss to follow-up.

  2. RFS (Recurrence-free Survival)

    Time frame: From the date of liver resection until the first occurrence of a measurable recurrence of the disease, or until death due to any cause (whichever occurs first), the assessment period can be up to 100 months.

    The definition of recurrence-free survival is the time from the liver surgery to the first imaging evidence showing disease recurrence or death due to any cause, whichever occurs first.

  3. HGPs (Histopathological Growth Patterns)

    Time frame: From the completion of HE staining to the failure of staining or the damage and loss of the slides, the assessment period can be up to 100 months.

    The histopathological growth pattern of the tumor-liver interface.

  4. TME (Tumor Microenvironment)

    Time frame: From the completion of mIHC staining to the failure of staining or the damage and loss of the slides, the assessment period can be up to 100 months.

    Multiplex immunohistochemistry (mIHC) staining was performed on FFPE sections of liver metastases using two panels (Panel 1: CD4, CD8A, Foxp3, PD-L1, Panck; Panel 2: CD68, CD163, FAP-α, α-SMA, Panck), encompassing a total of nine immune cell markers. Using QuPath pathology imaging software, tissue sections were divided into the tumor center (defined as regions >500 μm from the liver-tumor interface) and the invasive tumor front (defined as a 1 mm region extending 500 μm on either side of the liver-tumor interface). Quantitative analysis of immune cell populations was performed in the tumor center, the invasive tumor front, and regions corresponding to different histopathological growth patterns.

Sponsors and collaborators

Lead sponsor

Meng Qiu

Other

Registry information

Acronym: CRLM

Important dates

Study start
2018
Primary completion
2030
Study completion
2030
First posted
May 4, 2026
Registry last updated
May 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.